Outcome and Safety of Sorafenib in Metastatic Renal Cell Carcinoma Dialysis Patients: A Systematic Review-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Outcome and Safety of Sorafenib in Metastatic Renal Cell Carcinoma Dialysis Patients: A Systematic Review

Published:2016-08 Issue:4 Volume:14 Page:277-283
ISSN:1558-7673
Container-title:Clinical Genitourinary Cancer
language:en
Short-container-title:Clinical Genitourinary Cancer

Author:

Leonetti Alessandro,Bersanelli Melissa^ORCID,Castagneto Bruno,Masini Cristina,Di Meglio Giovanni,Pellegrino Benedetta,Buti Sebastiano^ORCID

Publisher

Elsevier BV

Subject

Urology,Oncology

Reference24 articles.

1. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial;Escudier;J Clin Oncol,2009

2. Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial;Hutson;Lancet Oncol,2013

3. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Escudier;Ann Oncol,2014

4. Kidney cancer, version 3.2015;Motzer;J Natl Compr Canc Netw,2015

5. European Association of Urology guidelines on upper urinary tract urothelial cell carcinoma: 2015 update;Rouprêt;Eur Urol,2015

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Association Between Kidney Function and Outcomes Following Immune Checkpoint Inhibitor-Based Combination Therapy in Patients With Advanced Renal Cell Carcinoma;Clinical Genitourinary Cancer;2024-04

2. Case report: Successful treatment of a patient undergoing haemodialysis with multifocal hepatocellular carcinoma using atezolizumab and bevacizumab;Frontiers in Oncology;2024-01-04

3. Overexpression of complement C5a indicates poor survival and therapeutic response in metastatic renal cell carcinoma;The International Journal of Biological Markers;2023-03-07

4. Combination Therapy of Pembrolizumab plus Axitinib for a Patient on Hemodialysis with Metastatic Renal Cell Carcinoma: A Case Report;Case Reports in Oncology;2021-10-22

5. Renal toxicity of targeted therapies for renal cell carcinoma in patients with normal and impaired kidney function;Cancer Chemotherapy and Pharmacology;2021-03-25

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3